<DOC>
	<DOCNO>NCT02546999</DOCNO>
	<brief_summary>In Norway , 60 % child cerebral palsy ( CP ) treat botulinum toxin A ( BoNT-A ) 6 year age , mainly legs . Despite widespread use drug , evidence positive effect walk insufficient . Moreover , large variation effect see clinician . The main objective present study investigate whether injection BoNT-A calf muscle make walk easy child spastic CP within 6 month , reflect reduce energy cost walking .</brief_summary>
	<brief_title>Does Botulinum Toxin A Make Walking Easier Children With Cerebral Palsy ?</brief_title>
	<detailed_description>This industry independent multicentre clinical trial . The randomization do computer number random generator carry held unit Applied Clinical Research NTNU . Two stratum : age center . The study conduct accord Consort guideline guideline Good Clinical Practice . It approve local Ethical committee ( REK Nord ) Norwegian Drug Agency . Primary research question : Do BoNT-A injection calf muscle make walk easy child CP ? Secondary research question : 1 ) Is improved ease walk associate increased activity ? 2 ) Is ease walk associate perceived benefit BoNT-A ? 3 ) Do BoNT-A injection calf muscle reduce recurrent musculoskeletal pain ? The participant receive treatment local anaesthesia conscious sedation oral nasal benzodiazepines.Outcome measure make baseline 4 , 12 24 week treatment , primary endpoint 12 week . Data analyze use linear mixed model ( LMM ) . Difference time effect primary outcome measure ( energy cost walk ) treat placebo group , post hoc test compare group difference baseline primary outcome measure 12 week post injection . Secondary , model use test effect also 4 24 week post injection . Subgroup analysis make accord age , use ankle foot orthosis , prior treatment botulinum toxin center . A substudy conduct within frame RCT , aim identify characteristic respond treatment compare respond ( outcome measure 7,8 9 ) .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Inclusion criterion : Diagnosed unilateral bilateral CP GMFCS level I II Signed informed consent expect cooperation patient treatment follow . BoNTA injection low leg last 6 month intervention history adverse reaction BoNTA Known hypersensitivity BoNTA excipients Orthopedic surgery legs last 2 year Major cognitive impairment ( must able take verbal instruction conduct test procedure ) infection propose injection site ( ) Subclinical clinical evidence defective neuromuscular transmission e.g . myasthenia gravis LambertEaton Syndrome patient peripheral motor neuropathic disease ( e.g . amyotrophic lateral sclerosis motor neuropathy ) underlie neurological disorder may affect BoNTA injection Use aminoglycoside antibiotic spectinomycin , medicinal product interfere neuromuscular transmission ( e.g . neuromuscular block agent ) Pregnant breastfeed Childbearing potential use contraception reason , opinion investigator , patient participate Children need deep sedation treatment</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Botulinum Toxins , Type A</keyword>
	<keyword>Walking</keyword>
</DOC>